Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study for the Adoptive Transfer of Re-directed FAP-specific T Cells in the Pleural Effusion of Patients With Malignant Pleural Mesothelioma.

NCT01722149 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT01722149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01722149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study for the Adoptive Transfer of Re-directed FAP-specific T Cells in the Pleural Effusion of Patients With Malignant Pleural Mesothelioma.
Lead sponsor
University of Zurich
Phase
Phase 1
Overall status
Completed
Start date
February 19, 2015
Completion date
July 18, 2019
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma